Ensifentrine

• CAT Number: I026888
• CAS Number: 1884461-72-6
• Molecular Formula: C26H31N5O4
• Molecular Weight: 477.56
• Purity: ≥95%

Ensifentrine (Cat No.: I026888) is a first-in-class, dual phosphodiesterase 3/4 (PDE3/4) inhibitor with both bronchodilator and anti-inflammatory properties. It increases intracellular cAMP by inhibiting PDE3 and PDE4, leading to airway smooth muscle relaxation and suppression of inflammatory cell activity. Ensifentrine has been extensively studied for chronic obstructive pulmonary disease (COPD) and asthma, where it improves lung function and reduces symptoms. Its dual mechanism provides advantages over conventional therapies, making it a promising candidate for respiratory disease treatment and ongoing clinical development.

Reference

[1]. Victoria Boswell-Smith, et al. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565
[Content Brief]

[2]. Henrik Watz, et al. Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis. Int J Chron Obstruct Pulmon Dis. 2020 Sep 16;15:2199-2206.
[Content Brief]